{"entity":{"id":"nct07407465","kind":"trial","name":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","aka":["CHIMERA"],"tldr":"A phase 2 trial of trastuzumab deruxtecan, capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.","summary":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. is a phase 2, interventional study registered as NCT07407465 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 42 participants, started 2025-10-20 and due to reach its primary completion in 2027-10-20. Interventions recorded: Trastuzumab-Deruxtecan (T-DXd); Capecitabine; Bevacizumab. Conditions listed: Colorectal Cancer; Colorectal Adenocarcinoma; Rectal Adenocarcinoma; Rectal Cancer, Adenocarcinoma; Rectal Cancer, Metastatic; Colon Cancer Metastatic; Colon Cancer Adenocarcinoma. Primary outcome: Overall Response Rate. Colorectal eligibility wording from the registry: \"* Have histologically documented adenocarcinoma of the colon or rectum, which is initially metastatic or unresectable locally advanced\". Sites: France, Germany, Italy, Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07407465","url":"https://clinicaltrials.gov/study/NCT07407465"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy"],"targets":[],"drugs":["trastuzumab-deruxtecan","capecitabine","bevacizumab-glioma"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07407465","phase":"2","setting":"Phase II Single Arm Study of Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer: the CHIMERA Study.","sponsor":"Gruppo Oncologico del Nord-Ovest","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07407465/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}